#### **Authors Conflict of Interest Disclosure Questionnaire**



Journal Circulation:Heart Failure Manuscript # CIRCHF/2019/006231R1

**IP Address** Date August 23, 2019 21:14 GMT 128.252.31.129

Baseline characteristics of the Valsartan

for Attenuating Disease Evolution in Early **Title** Sarcomeric Hypertrophic Cardiomyopathy

cohort

Anna Axelsson Raja, Ling Shi, Sharlene Day, Mark Russell, Kenneth Zahka, Harry Lever, Steven Colan, Renee Margossian, E. Kevin Hall, Jason Becker, John Lynn Jefferies, Amit Patel, Lubna Choudhury, Anne Murphy, Charles Canter, Richard

Bach, Matthew Taylor, Luisa Mestroni, Authors

Matthew Wheeler, Lee Benson, Anjali Owens, Joseph Rossano, Kimberly Lin, Elfriede Pahl, Alexandre Pereira, Henning Bundgaard, Gregory Lewis, Jose Vargas, Allison Cirino, John McMurray, Calum MacRae, Scott Solomon, E. John Orav, Eugene Braunwald, and Carolyn Ho

#### Instructions for Authors Conflict of Interest Disclosure

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form includes the questions from the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest and is divided into 6 subsections. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information.

Authors are expected to provide detailed information about all relevant financial interests, activities, relationships, and affiliations (other than those affiliations listed in the title page of the manuscript) including, but not limited to, employment, affiliation, funding and grants received or pending, consultancies, honoraria or payment, speakers bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents and copyrights planned, pending, or issued.

## 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was

supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by

the entity, writing assistance, administrative support, etc **Other:** Anything not covered under the previous 3 boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

# **Section 1. Identifying Information**

Author: Richard Bach

Date: August 23, 2019

☐ I am the Corresponding Author

Manuscript Title: Baseline characteristics of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy cohort

Manuscript Identifying Number: CIRCHF/2019/006231R1

## Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc)?

No

# Section 3. Relevant Financial Activities Outside the Submitted Work

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use 1 line for each entity; add as many lines as you need by clicking the "Add" button to add a row. Excess rows can be removed by pressing the "Remove" button. You should report relationships that were **present during the 36 months prior to submission**.

#### Yes

- CSL Behring grants
   Institutional grant for clinical trial only
- MyoKardia grants
   Institutional grant for clinical trial only
- Cirius Therapeutics, Inc personal fees CEC activity only
- Novo Nordisk personal fees CEC activity only

# Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents or copyrights, whether planned, pending, or issued, broadly relevant to the work?

No

# **Section 5. Relationships Not Covered Above**

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, the journal will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, the journal may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement in the box below after you click the "Generate Disclosure Statement" button. Any subsequent changes will also update the disclosure statement automatically after clicking the "Submit" button.

Dr Bach reports grants from CSL Behring, grants from MyoKardia, personal fees from Cirius Therapeutics, Inc, and personal fees from Novo Nordisk outside the submitted work. By completing this form, I confirm that the information reported is accurate. I understand that, where appropriate, this information may be disclosed publicly. I further understand that the American Heart Association, Inc., reserves the right to decline to publish my work if the Organization believes a significant conflict of interest exists.

Richard Bach

Checking this box acts as your signature for the Authors Conflict of Interest Disclosure Questionnaire.

August 23, 2019 21:14 GMT

local\_p\_id: 540534 time: 1566595204

ip address: 128.252.31.129